Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2012

View Archived Issues

Trials reveal efficacy of REGN-727 in treating hypercholesterolemia

Studies further delineate clinical efficacy of mipomersen

Detailed phase II data disclosed on solithromycin at ECCMID

Novel imidazopyridines identified as potential hepatitis C therapeutics

Exenatide shows potential as a cardioprotective agent

Novel acetyl-CoA carboxylase 2 inhibitors prepared at Boehringer Ingelheim

Spanish scientists patent new apoptosis-inducing agents

New histamine H3 receptor ligands disclosed by Suven Life Sciences

Novel protein kinase inhibitors patented by Suzhou Ascepion Pharmaceuticals

Encouraging data on multikinase inhibitor support clinical development

Shionogi-ViiV Healthcare reports initial data from phase III dolutegravir trial

Actelion's miglustat obtains approval in Japan

Treatment starts in first-in-human rVIIa-FP study

Actelion focuses on follow-up prostanoid DP2 receptor antagonist

Shire reports topline results from PREVENT2 trial

Novartis Nanobody candidate clear to enter phase I trial

Raptor Pharmaceutical submits NDA for RP-103

Alfresa Pharma files application in Japan for tetrabenazine

Synageva BioPharma and Mitsubishi Tanabe Pharma expand collaboration

Keryx Biopharmaceuticals reports topline data from X-PECT

PLx Pharma receives grant for research into treatment for heart defect in premature babies

FDA approves Levemir label update

PolyTherics and Spirogen to collaborate on novel ADCs for cancer

Minirinmelt tablets approved in Japan

Nektar commences dosing in phase I study of new short-acting opioid for acute pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...